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A clinically efficacious Ras inhibitor has eluded drug-discovery efforts for decades. In a paper in
Nature, Zimmermann and et al. show that blocking a hole in PDEd that normally engages the lipid
tail of Ras disrupts downstream signaling, pointing to a potentially promising route to develop Ras
inhibitors for cancer treatment.Activating Ras mutations are found very
frequently in human cancers (Schubbert
et al., 2007). In particular, mutations in
the K-Ras isoform are prevalent in cer-
vical, lung, pancreatic, and colorectal
cancers and are associated with a poor
prognosis. Unfortunately, no clinically
viable drugs have yet been developed to
inhibit Ras signaling directly. Ras binds
to guanosine diphosphate and guanosine
triphosphate (GTP) with picomolar affin-
ity, making it challenging to develop
competitive inhibitors for the nucleotide-
binding pocket, given the abundance of
free nucleotides in the cell. An intense
effort to block Rasmaturation by targeting
Ras farnesyl transferases appears to have
stalled. Given the demand for small mole-
cule inhibitors that target Ras signaling,
investigators have been searching for
alternative approaches to achieve this
end. In a recent issue of Nature, Zimmer-
mann et al. (2013) report exciting newfindings on the inhibition of Ras signaling
by targeting the Ras-binding protein
PDEd, which has a deep pocket that ap-
pears most welcoming to small molecules
(Zimmermann et al., 2013).
Ras activity arises from the combined
actions of guanine nucleotide exchange
factors, which cause the release of bound
nucleotide and subsequent binding of
GTP, and GTPase activating proteins
(GAPs) that accelerate hydrolysis of Ras-
bound GTP (Cherfils and Zeghouf, 2013).
Oncogenic Ras mutations subvert GAP-
induced GTP hydrolysis, leading to
constitutive signaling. An additional level
of regulation is made possible by the
fact that lipid modifications at the C termi-
nus of Ras-family proteins are necessary
for function. These lipid anchors control
the final destination within the cell of
different Ras isoforms and limit the free
diffusion of the proteins through the cyto-
plasm. PDEd controls the intracellularlocalization of Ras-like proteins by bind-
ing to their farnesyl tails (Figure 1). In this
way, PDEd enhances the cytoplasmic
diffusion of Ras, allowing it to distribute
to the proper subcellular compartments
where signaling is initiated (Chandra
et al., 2012; Nancy et al., 2002).
PDEd was discovered originally as a
subunit of phosphodiesterase 6 (PDE6)
in photoreceptor cells, where it likely
plays a role in binding to the lipid tails of
the PDE6 catalytic subunits. The farnesyl
anchor at the C terminus of Ras and other
proteins is recognized by a hydrophobic
hole in the immunoglobulin-like b sand-
wich fold of PDEd (Ismail et al., 2011).
The action of PDEd is similar to that of
Rho guanine nucleotide dissociation in-
hibitors (GDIs) (Hanzal-Bayer et al.,
2002), which also use a b sandwich fold
to recognize the geranylgeranyl moiety
of the Rho GTPase. RhoGDIs employ a
second domain to contact the switch I53, June 6, 2013 ª2013 Elsevier Inc. 1191
Figure 1. Regulation of GTPase Trafficking by PDEd
Ras family G-proteins such as Rheb (orange) bind to PDEd using a farnesylated cysteine residue at the C terminus that is shown in ball and stick representation
(left). The lipid molecule is buried deep within the core of the b sandwich of PDEd. Zimmermann and coworkers have developed benzimidazole-based com-
pounds that disrupt the interaction between PDEd andK-Ras by binding in the cavity of PDEd (right). Thesemolecules prevent proper cellular localization of K-Ras
and inhibit signaling.and switch II regions of the GTPase (Gar-
cia-Mata et al., 2011), but this helical re-
gion is not conserved in PDEd (Ismail
et al., 2011). Because the nucleotide-
bound state of the G protein is not sensed
by PDEd, the interaction between the two
proteins is regulated by other mecha-
nisms. For example, the binding of
Arl2$GTP or Arl3$GTP allosterically in-
duces PDEd to relinquish its cargo (Han-
zal-Bayer et al., 2002; Ismail et al.,
2011), as demonstrated by structural
and biophysical studies.
Given the importance of PDEd in proper
Ras localization, Zimmermann and col-
leagues speculate that compounds de-
signed to disrupt Ras binding to PDEd
might have a profound and desirable ef-
fect on Ras signaling. By using a high-
throughput screen, they uncover a series
of benzimidazole molecules that inhibit
the Ras-PDEd interaction by plugging
the farnesyl-binding cavity. Structural
analysis plays a key role in optimizing
these compounds because it reveals
that two benzimidazole molecules bind
side-by-side to PDEd. This unexpected
finding motivates the synthesis of addi-
tional analogs that connect the benzimid-1192 Cell 153, June 6, 2013 ª2013 Elsevier Inazole moieties via short linkers, leading to
more potent inhibitors with low-nanomo-
lar affinity for PDEd in vitro.
Using fluorescence lifetime imaging mi-
croscopy-based measurements, the au-
thors show that one such compound
(termed Deltarasin) disrupts the interac-
tion between PDEd and K-Ras in cells
and results in the redistribution of K-Ras
to endomembranes rather than the
plasmamembrane. Furthermore, Deltara-
sin increases cell death of a cancer cell
line that relies on K-Ras for survival but
is not toxic to cells that survive indepen-
dently of K-Ras signaling.
Previous efforts to identify inhibitors of
Ras signaling have employed a range of
different strategies (Baines et al., 2011).
The discovery of the enzymes responsible
for modification and lipidation of the
C-terminal region of Ras generated
tremendous excitement for attempts to
inhibit this machinery. However, the pro-
cessing enzymes have many protein tar-
gets, and inhibition of the Ras farnesyl
transferase leads to compensation by a
second lipid-modifying enzyme. Other
screens have focused on downstream
effectors of Ras such as Raf kinase.c.Although this strategy is promising in the
treatment of some cancers, Ras activates
many other effectors that promote on-
cogenesis. Recent searches for inhibitors
that target Ras more directly by using a
fragment-based lead discovery approach
have led to the identification of com-
pounds that bind to a pocket on Ras
adjacent to the switch I and switch II
elements (Maurer et al., 2012). Molecules
from this screen were shown to inhibit
SOS-mediated nucleotide exchange
in vitro but are severely lacking in
potency.
The work from Zimmermann and co-
workers represents a novel strategy for
combating oncogenic Ras mutations. It
remains to be seen if inhibitors of the
Ras-PDEd interaction will succumb to
the same pitfalls as other Ras-targeting
therapies. It is encouraging to note that
Deltarasin does not bind to other GDI-
like solubilizing proteins. Additionally,
Deltarasin reduces the growth rate of tu-
mor-cell xenografts in mice. However,
because PDEd primarily interacts with
the farnesyl group of K-Ras, Deltarasin
may also disrupt signaling by other
GTPases such as Rheb or Rap in cells.
Regardless, this work represents an
exciting new avenue in the pursuit of
Ras inhibitors for the treatment of cancers
and developmental diseases because the
hole in PDEd seems so eminently drug-
gable. It is also gratifying to see how the
continuing investigations into the mys-
teries of Ras signaling have illuminated
this particular target and might reveal
others in the future.
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